Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis.

Courtney JohnsonJennifer StephensChristopher WalkerJoseph Christopher CappelleriAhmed Shelbaya

Published in: ClinicoEconomics and outcomes research : CEOR (2020)

Patients that switched from branded celecoxib to a generic NSAID or received an under-dose of branded celecoxib had higher average overall HCRU and costs. OA-related inpatient and outpatient cost savings may offset the higher drug cost of celecoxib for persistent patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
knee osteoarthritis
rheumatoid arthritis
type diabetes
metabolic syndrome
mental health
skeletal muscle
health insurance
patient reported outcomes